Division of Pediatric Gastroenterology and Nutrition, Children's Hospital Research Foundation, Cincinnati, Ohio. Our objective was to identify and characterize the Na:TR cotransporter on the rat hepatic basolateral membrane (BLM). TR transport by highly purified hepatic BLM prepared from 14d and adult rats was inhibited 40.50% following exposure to the sulfhydryl (SH) modifying reagent. N-ethylmaleimide (NEM) (250pM). Preincubation of BLM with TR (100pM) prior to exposure to NEM protected TR transport activity. In contrast, phenyl glyoxal (100-250fiM) and phenylisothiocyanate (SOOpM), reagents which modify arginine and lysine amino groups respectively, did not inhibit Na-dependent TR transport. BLM from 14d and adult rats was analyzed by SDS-PAGE to determine if increased TR transport activity in suckling compared to adult rats is due to quantitative differences in the carrier protein. Increased band densities were noted at apparent MW of 72, 38 and 36 kDa in 14d compared to adults. Conclusion: A SH group at or near the TR binding site is essential for Na:TR cotransport by rat hepatic BLM. Preliminary work by our group has demonstrated a human placental 72 kDa protein with 34 and 38 kDa subunits associated with Na:TR cotransport. The increased expression of proteins of similar MW in suckling rat liver suggests that they may be components of the putative TR transporter. Increased ontogenic expression in combination with labeling of a substrate protec- (Gastroenterol 1982; 82:1295) . The present study was designed to test the hypothesis that infants with IR/D will develop biliary cholesterol supersaturation after puberty presumably because of the inrluence of sex hormones in biliary secretion. Five sexually mature subjects (3M, 2F, agc 16-19 yr) who had been previously investigated in childhood (ages 4-9 yrs) were studied. Ultrasound examination of the gallbladder performed using real-time sonography rcvcnled gallstones on one subject. Duodenal bile samples, obtained .lTter an overnigllt fast, were examined for bile acids ( U A ) , phosphulipid (PL) and cholesterol (XOI.), and the molar fraction (El%) and lithogenic index (LI) calculated. Comparisons are shown between subjects prior to puberty (C), post puberty (Pl') and 20 young adult controls [x+SEH, *p c.001 or +p <.005 vs. lleal disease (PI')]:
XOl The gene responsible for CF has been cloned. In the majority of CF patients a 3 base pair deletion results in \he loss of a pl~enylalanine residue at Lhe 508 position (AF) of Lhc putative gene. At least 7 othet mutations are predicted, which may account for the variable clinical phenotypes. Our previous genetic analysis showed that patients wiLlr or wiLl~out pancreatic function (PS and PI) possess different mutant alleles. We have further characterized the relationships between the CF gene mutations and various aastrointestinal manifestations in 261 CF patients (Table) . These data also suggest: (1) Phenotypic variations of it~testinal, outritiu~~al and prrl~sonary disease in CF correlate wiLh the nature of mutations in the gene; (2) AFlAF confers a severe phenotype; (3) additional mild and severe mutations exist. ' ' U i i u e r r i t r 61 Celifornis, LO. Angeles, USA. One patient with HAY died port.operatively u l t h i r r e v e r s i b l e neurological dorwge but norm1 g r a f t function; trsnsplantetian uas done u h i l e i n stage IV c m . 3 patients survived ulthaut transplantation. (1. HBV and 2. NANB) and only one shoued moderate l i v e r dysfunction u i t h severe architectural dsmge and regeneration histologically.
P r i o r t o developnent of orthotopic l i v e r transplantation (OLT), m o r t a l i t y of FllF i n p e d i a t r i c patients was 80.85%. OLT has been e major factor i n reducing m o r t a l i t y (ran t h i s condition. T h i r t y p e d i a t r i c patients, median age 4 y r r (range 3 ma. t o 17 yrs.) presented with FHF from h e p a t i t i s of wkovn e t i o l o g y (NAME)
The presence of a r c i t e s was a good c l i n i c a l predictor f o r f a t a l outcane. OLT s u b~t a n t i a l l y reduces m o r t a l i t y f r a n THF and should be considered i n any p o t i c n t who 
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Angeler. USA P r u r i t u s is, without B doubt. the r e s t frequent and uncomfortable synptan of severe cholestasis. I t s etiology and physiopathology are s t i l l rnslear but are believed linked t o b i l e salts. Therapy has t r a d i t i o n a l l y consisted o f a h i n i s f r a t i o n of phenobarbital, antihistamines, b i r d i n g resins, plasmapheresis and m l l i e n t s uithout reduction i n s r n t a n r . Ue report r e s u l t s of therapy with r i f a w i n (an agent that reduces b i l e a c i d uptake) i n s series of p e d i a t r i c patients with severe cholestanis r y n d r m r who had f a i l e d t o respond t o classic treatments (cholentyramine and phemberbital). Twenty me children, 11 males i n s group representative o f a l l p e d i a t r i c ages, (0-1 yr=5, 1-3 yrs=5, 3-6 yrs=5, and 6-17 yrr=6), u i t h severe cholestssis and p r u r i t u s secondary t o B i l i a r y A t r e r i e (11). Familial Cholertasis (3). B i l i a r y Hypoplerie (2). Neonatst Hepatitis (2). Cystlc Fibrosis (1). H-ngioendathetima post-extensive resection (1) and Cholertasis o f unknown e t i o l o g y (1).
Yere given a course o f 5 mgjKgl day o f Pifanpin, o r a l l y . A net improvment, u i t h d i s e p a r a n c e o f p r u r i t u s u i t h i n 7 days of treatmnt, was observed i n 50% of the patients. The r e s t o f the patients inproved, u i t h decreased i t c h -r e v e r i t y scales (subjective parameters by parent or child), t o the point of t o t a l control i n a l l cases except one, u i t h i n a range o f 1-28 ueeks o f therapy. No change or deterioret i o n o f l i v e r chemistries or synthetic function, blood C m t r , or choliglyeine levels uere observed during a period f r m 4 ueekr t o 2 years o f therapy. No complications uere recorded and the medication was well tolerated. Rifampin i s a safe and e f f e c t i v e drug t o t r e a t severe p r u r i t u s i n c h o l e s t s t i c infants and children.
